Essentials
• Marzeptacog alfa (activated) [MarzAA] is a novel variant of activated human factor VII.
• A phase 1 dose escalation trial of MarzAA was conducted in subjects with severe hemophilia.
• MarzAA was safe and tolerated at intravenous doses up to 30 lg kg
À1
• Data observed support further trials for hemophilia patients with inhibitors to factors VIII/IX.
Summary. Background: Marzeptacog alfa (activated) (MarzAA), a new recombinant activated human factor VII (rFVIIa) variant with four amino acid substitutions, was developed to provide increased procoagulant activity and a longer duration of action in people with hemophilia. Objectives: To investigate the safety, tolerability, immunogenicity, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending intravenous bolus doses of MarzAA in non-bleeding patients with congenital hemophilia A or B with or without inhibitors. Methods: This international, phase 1, openlabel study (NCT01439971) enrolled males aged 18-64 years with severe hemophilia A or B, with or without FVIII or FIX inhibitors. Subjects were assigned to singledose MarzAA cohorts (0.5, 4.5, 9, 18 or 30 lg kg À1 ).
Blood sampling was performed predose and postdose, and subjects were monitored for 60 days postdose. Safety endpoints included adverse events, vital sign changes, electrocardiograms, laboratory abnormalities, and immunogenicity; secondary endpoints included evaluation of PK and PD. Results: Overall, in 25 patients, MarzAA was well tolerated at all dose levels tested, and was not associated with dose-limiting toxicity. No treatment-emergent severe or serious adverse events occurred. MarzAA showed linear dose-response PK across the 4.5-30 lg kg À1 dose range, with a terminal half-life of ⁓ 3.5 h.
Dose-dependent shortening of the activated partial thromboplastin time and prothrombin time, and evidence of an increase in peak thrombin as determined with a thrombin generation assay, were observed at all doses. Conclusions: MarzAA was tolerated at doses up to 30 lg kg
Introduction
Hemophilia, a hereditary X-linked blood clotting disorder, caused by a deficiency of factor VIII (hemophilia A) or FIX (hemophilia B), is characterized by spontaneous or traumatic bleeding events [1, 2] . Repeated episodes of hemarthrosis may lead to arthropathy [1, 2] . For patients with severe hemophilia, routine prophylaxis with coagulation factor replacement has reduced the frequency of bleeding episodes and prevented joint disease [1, [3] [4] [5] . A major and serious treatment complication is the development of neutralizing antibodies (inhibitors) against FVIII or FIX, which may preclude the establishment of hemostatic levels of FVIII or FIX [1] . For hemophilic patients with inhibitors of FVIII or FIX, hemostatic therapy can be achieved with bypassing agents, including human activated recombinant FVII (rFVIIa; eptacog alfa [activated], NovoSeven; Novo Nordisk, Bagsvaerd, Denmark) or activated prothrombin complex concentrates (FEIBA; Baxalta, Bannockburn, IL, USA). The efficacy of bypassing agents is well established; however, there are several limitations to their hemostatic efficacy in patients with inhibitors, including the proportion of patients achieving prompt hemostatic resolution of bleeding episodes, or a reduction in the annualized frequency of bleeding episodes during routine prophylaxis, as compared with clotting factor replacement therapy in the absence of inhibitors [3, 4, [6] [7] [8] [9] [10] . Variable intrapatient and interpatient responses to treatment also exist [11] [12] [13] . These limitations may be attributable to: suboptimal thrombin generation and clot formation; competition for binding to tissue factor (TF) with endogenous FVII; the intrinsically weak enzymatic activity in the absence of TF; and inactivation by TF pathway inhibitor (TFPI) or antithrombin [14] [15] [16] [17] [18] . Additionally, the half-life (t 1/2 ) of these agents is short, necessitating frequent administration, which may be time-consuming and inconvenient for patients, impeding optimal prophylactic use [13, [19] [20] [21] . A bypassing agent with favorable pharmacokinetics (PK) and hemostatic properties, including increased potency and a prolonged duration of effect, may help to address an existing unmet medical need in hemophilic patients with inhibitors.
Marzeptacog alfa (activated) (MarzAA, formerly known as PF-05280602) is a variant of rFVIIa with site-directed changes of four amino acids made by the use of standard molecular biology techniques (Fig. S1) . Two of these changes are located within the catalytic domain (Gln286 to Arg [Q286R]; Met298 to Gln [M298Q]) and result in increased binding to activated platelets and TF-independent activation of FX, leading to improved procoagulant activity [22, 23] . Two additional changes made to adjacent amino acids (Thr128 to Asn [T128N]; Pro129 to Ala [P129A]) introduced a new site for N-linked glycosylation, which was intended to increase the circulating t 1/2 of MarzAA as compared with wild-type rFVIIa [24] . N-glycosylation can influence protein properties, such as stability, bioactivity, and plasma t 1/2 [25] . In preclinical (mouse and dog) studies and in vitro studies, MarzAA showed a six-fold to seven-fold increase in TF-dependent catalytic activity for activated FX generation, a 10-fold increase in TF-independent catalytic activity, and an increased duration of pharmacodynamic (PD) effect relative to eptacog alfa (activated), as measured according to thromboelastographic parameters [22] [23] [24] . MarzAA is intended for routine prophylactic use, to prevent or reduce the frequency of bleeding episodes, and perioperative management in adults with hemophilia A or B with inhibitors.
The objectives of this phase 1, first-in-human, doseescalation study were to investigate the safety, tolerability, PK, pharmacodynamics (PD) and immunogenicity of single ascending intravenous bolus doses of MarzAA in non-bleeding subjects with severe hemophilia A or B with or without inhibitors of FVIII or FIX.
Materials and methods
The trial was registered at Clinical-Trials.gov (Registration Number: NCT01439971).
Study population
The study was conducted in accordance with the International Council for Harmonization Good Clinical Practice guidelines and with national and local laws and regulations. The study protocol and all amendments were reviewed and approved by the institutional review board or independent ethics committee at each participating study site. All subjects or their legally authorized representative were required to provide written informed consent prior to participation in the study.
Subjects , a hemoglobin level of ≥ 10 g dL À1 , a fibrinogen level above the lower limit of the reference range, a prothrombin time (PT) of ≤ 1.25 times the upper limit of the reference range, and a willingness to comply with study washout requirements for screening and before dosing. Subjects receiving therapy for active hepatitis or HIV must have been receiving stable therapy for at least 3 months before study entry. All subjects were also required to and be willing to use effective contraception until day 30 after study drug administration. Females, and individuals with known hypersensitivity to hamster protein or eptacog alfa (activated), with a history of coronary artery disease, with thrombotic disease or a diagnosis of prothrombotic disorder, using regular, concomitant therapy with immunomodulating drugs or with a bleeding disorder other than hemophilia A or B were excluded. All subjects were in a non-bleeding state at the time of screening and drug administration.
Study design
Under the original study protocol, the starting dose level of MarzAA was 0.5 lg kg
À1
. A protocol amendment revised the starting dose level to 4.5 lg kg
. The initial protocol reflected a minimum anticipated biological effect level (MABEL) calculation based on starting at the projected EC20; however, on the basis of the extensive clinical experience with this mechanism of action in hemophilic patients, agreement was obtained from regulatory authorities that the starting dose could be revised on the basis of MABEL calculations starting at EC46 (for hemophilia A plasma) and EC29 (for hemophilia B plasma). Six eligible subjects within each of the four cohorts were given ascending single doses of MarzAA of 4.5, 9, 18 and 30 lg kg À1 , via slow intravenous infusion over a period of ≤ 2 min. A washout of all hemostatic treatments at least 72 h (96 h for FIX) before dosing was required; this pause in treatment was continued for 48 h postdose. In the 4.5 lg kg À1 and 9 lg kg À1 cohorts, enrollment was paused after the first subject had been dosed, to allow for review of safety data through post-treatment day 3, before the remainder of the cohort was dosed. For an event meeting dose escalation stopping rule criteria (Data S1), the enrollment pause was applied to the next two subjects before the final three subjects were enrolled in the respective cohort. In the 18 lg kg À1 and 30 lg kg À1 cohorts, the enrollment pause was applied to each of the first three subjects dosed. If any event meeting dose escalation stopping rule criteria occurred in the first three subjects, the enrollment pause was applied to all remaining subjects in the respective cohort. Each dose escalation was approved only after review of the safety, PK and PD data up to post-treatment day 15 by the sponsor and external data monitoring committee. Escalation to the next higher dose proceeded only if no safety and tolerability concerns were identified, especially for dose-limiting toxicity. Abnormal laboratory, electrocardiogram (ECG) or vital sign findings meeting protocol-defined quantitative criteria for stopping rules required additional assessment by the respective study investigator for clinical significance. Two or more similar treatment-emergent, clinically significant events meeting the prespecified quantitative criteria in a given cohort would trigger a stop in dose escalation.
Safety and immunogenicity assessments
The initial screening period was followed by a 3-day inpatient period (Data S2). During that time, subjects were given a single intravenous bolus dose of MarzAA on day 1, and then monitored through day 3. A safety follow-up was conducted at day 15. Safety assessments included adverse events (AEs), hemophilic events, physical examination, ECG, vital sign collection, telemetry monitoring, urinalysis, plasma sample collection for chemistry, hematology parameters, fibrinogen, antithrombin III, TFPI, troponin T, C-reactive protein, PT, and day 15 D-dimer. Immunogenicity assessment specimens were collected at the day 1 pretreatment baseline and on days 15, 30, and 60. Evidence of a neutralizing or nonneutralizing antibody immune response at day 30 or day 60 triggered additional immunogenicity follow-up at 6 months and 9 months post-treatment. Immunogenicity testing included antidrug (anti-MarzAA) antibody (ADA), inhibitor of MarzAA (neutralizing antibody), and FVII activity. The ADA analysis was performed with a tiered approach of screening, confirming specificity, and characterizing the titer with a semiquantitative ELISA. For ADA samples confirmed to be positive but negative during titer characterization, the titer was reported as the minimal dilution used (25 for this study). Any positive ADA or inhibitor samples were further characterized for cross-reactivity to eptacog alfa (activated) and native human FVII. An antibody immune response for a subject was operationally defined as a confirmed post-treatment positive ADA result in combination with a negative baseline result, or a confirmed post-treatment positive ADA result in combination with at least a 0.3012 increase in log titer relative to a positive baseline result. Inhibitor of MarzAA was tested with a validated Nijmegen modification of the Bethesda inhibitor assay on the Stago STA Compact machine (Diagnostica Stago, Parsippany, NJ, USA). A positive inhibitor response was operationally defined as either a confirmed post-treatment positive inhibitor assay result or at least a ≥ 50% depletion of FVII activity in the absence of any other plausible explanation.
PK assessments
For PK assessments, blood samples were collected predose and at 5, 10, 20 and 30 min and 1, 3, 6, 9, 12, 24 and 48 h postdose. Samples were analyzed with the STA-CLOT FVIIa-rTF kit (Diagnostica Stago) on the Stago STA Compact machine. Both endogenous FVIIa and MarzAA were detected in the assay. The lower limit of quantification for the assay was 0.07 ng mL À1 . The following plasma PK parameters were calculated for each subject for each treatment, as applicable, with noncompartmental analysis of plasma concentration-time data: maximum plasma concentration (C max ), time to C max (T max ), t 1/2 , area under the plasma concentrationtime curve (AUC) from time 0 to the time of the last quantifiable concentration (AUC last ), AUC from time 0 extrapolated to infinite time (AUC inf ), clearance (CL), volume of distribution at steady state (V ss ), incremental recovery, mean residence time, time to the last quantifiable concentration, dose-normalized C max , dose-normalized AUC last , and dose-normalized AUC inf .
PD assessments
Citrated plasma samples were collected for 48 h postdose for assessment of the PT, the activated partial thromboplastin time (APTT), prothrombin fragment 1 + 2 (F 1+2 ), thrombin-antithrombin (TAT) complexes, D-dimer, and thrombin generation assay (TGA). The TGA was performed with platelet poor plasma low reagent (Diagnostica Stago), with lag time, peak thrombin and endogenous thrombin generation potential (ETP) being reported.
Statistical analysis
The safety analysis population was defined as all subjects who received study drug. Subjects were analyzed by cohort, and all subjects with at least one PK sample or PD sample evaluated were included in the respective analysis. Descriptive statistics were used to summarize all demographic, hemophilia history, safety, PK and PD data, by treatment group. PK parameters, including C max, T max , AUC inf , t 1/2 , V ss , and CL, were calculated with non-compartmental analysis. For t 1/2 calculation, only concentrations that were at least twice the baseline values were used. If the predose value was > 5% of C max for each individual, the baseline value was subtracted from all postdose PK concentration values (only one subject in the 0.5 lg kg À1 dose group was adjusted, as the baseline value was 40% of the C max ).
Results

Subjects
This international, phase 1, open-label, single-dose escalation study in non-bleeding subjects with hemophilia was Baseline demographic and hemophilia disease characteristics are outlined in Table 1 . Most subjects (68%) were white, and the mean age was 37.2 years (range: 21-62 years). The mean weight and BMI were 76 kg and 24.7 kg m À2 , respectively. Four subjects had severe hemophilia B (FIX activity of ≤ 1%) and 21 had severe hemophilia A (FVIII activity of ≤ 1%) based on screening assessments as measured with a one-stage clot assay, eight subjects (32%) had a history of inhibitors (all of these had hemophilia A), and five subjects (20%) had prior exposure to eptacog alfa (activated). The demographic characteristics were similar across all of the dosing groups. All 25 subjects completed the study and were included in the safety analyses.
Pharmacokinetics
Median FVIIa concentration-time profiles for each dose group are shown in Fig. 1 . The summary of PK parameters for MarzAA is shown in Table 2 . The PK parameters are not reported for the one subject who received the lowest dose of 0.5 lg kg À1 .
All subjects had detectable endogenous FVIIa levels predose. Following intravenous bolus administration, MarzAA C max was reached between 5 min and 22 min postdose. Both C max and AUC inf dose-dependently increased across the 4.5-30 lg kg À1 dose range. C max appeared to increase slightly more than dose proportionally in the 4.5-18 lg kg À1 dose range, but appeared to be 
Pharmacodynamics
Three subjects were excluded from the PD analysis -one subject treated with a dose of 0.5 lg kg À1 MarzAA; one subject treated with a dose of 9 lg kg À1 who had an FIX value of 3% at baseline (despite having an FIX value of ≤ 1% at screening); and one subject treated with a dose of 9 lg kg À1 who received FVIII replacement treatment before the 12-h time point; hence, subsequent time points for this subject were also excluded. Treatment-related dose-dependent shortening of the PT and APTT was observed for MarzAA doses ranging between 4.5 lg kg À1 and 30 lg kg À1 (Fig. 2) . Maximum mean PT and APTT reductions were observed between 30 min and 1 h postdose, and the values returned to baseline by ⁓ 48 h. At the highest dose tested (30 lg kg À1 ), the mean PT reduction at 1 h postdose was 4.5 s, and the mean APTT reduction at 30 min postdose was 46.9 s. Dose-dependent changes in peak thrombin, lag time and ETP in the TGA were also observed (increase in peak and ETP; reduction in lag time) at all dose levels. Median peak thrombin versus time profiles by dose are shown in Fig. 2C . A potential dose-dependent F 1+2 increase was also observed (Fig. 2D) . Maximum median F 1+2 increases were delayed as compared with the PT, APTT and TGA assays; they were observed between 1 h and 6 h postdose, and the values returned to baseline between 24 h and 48 h. At the highest dose tested, the maximum median increase in F 1+2 was 215.5 pmol L À1 at 6 h. Data for TAT complex (reference range: 1-4.1 lg L
À1
) were highly variable, and a treatment-related increase was most prominent at the highest dose ( Fig. S2A; Table 3 ). The maximum median TAT complex increases were observed between 1 h and 12 h postdose, and the values returned to baseline between 24 h and 48 h. The maximum median increase at 30 lg kg À1 was 18.4 lg L À1 at 6 h ( Table 3) . There was a possible treatment-related D-dimer (Table 3 ; Fig. S2B ) increase at the highest dose, with the maximum increase being observed between 6 h and 12 h postdose; however, no clear dose response was observed (Fig. S2) . One subject (receiving a 30 lg kg À1 dose) had an elevated D-dimer level on study day 15, with a normal baseline value (reference range: 0-500 ng mL
).
Safety and tolerability
Treatment-emergent AEs (TEAEs) are presented as nonhemophilia-related (Table S1 ) and hemophilia-related (Table 4) AEs. All TEAEs were mild or moderate in severity. No AEs led to study discontinuation. Events deemed to be related or possibly related to study drug included increased blood creatinine and blood urea levels in one subject, and dizziness, tinnitus and dysgeusia in one subject each; each event was mild in severity. No thrombotic events occurred. Protocol stopping rules for dose escalation were not triggered at any dose level. Similar clinically significant laboratory abnormalities or vital sign abnormalities meeting quantitative stopping criteria did not occur in more than one subject at any dose level. None of the vital sign abnormalities were deemed to be clinically significant by the study investigators.
Immunogenicity
There were no subjects with neutralizing antibodies against MarzAA, and there were no subjects with > 50% reduction of FVII activity relative to baseline. A single subject who had baseline ADA and postbaseline ADA assay values close to the cut-off point that were much higher than those of all other subjects received a dose of 18 lg kg À1 and showed a weak, transient positive ADA result that was non-neutralizing at a single time point of day 60 postdose. This subject had no history of inhibitors of coagulation factor products and had no prior exposure to rFVIIa products. The respective sample was positive during the confirmation step, but was negative during titer characterization; therefore, the titer was reported as 25 on the basis of the predefined procedure. The ADA was characterized as being cross-reactive with eptacog alfa (activated) and with native human FVII. This subject was negative for ADAs at the subsequent assessment, the inhibitor assay gave negative results at all scheduled time points, including day 60, and the subject's FVII activity level was not reduced by > 50% at any visit relative to baseline. Additional review of the raw data from the ADA assay suggested that this finding did not have clinical relevance and was probably a false positive result.
Discussion
This phase 1, first-in-human study evaluated the safety, tolerability, PK and PD parameters and immunogenicity of escalating single doses of MarzAA, ranging from 0.5 lg kg À1 to 30 lg kg À1 , in 25 subjects with severe hemophilia A or B with or without inhibitors. Single administrations of MarzAA at all dose levels tested were safe and tolerated, with no serious AEs being reported. No enrolled subjects withdrew from the study. Dosedependent increases in PK exposure and changes in PD parameters were observed. The plasma concentrations of MarzAA were found to be dose-dependent across the range of doses (0.5-30 lg kg À1 ) evaluated. Clearance and V ss appeared to decrease across the dose range of 4.5-18 lg kg À1 , but remained similar for the 18-30 lg kg À1 dose levels. As both CL and V ss showed dose-dependent decreases, the resulting t 1/2 of MarzAA was similar across all dose groups (∼3.5 h). In comparison, the t 1/2 of eptacog alfa (activated) has been found to be ⁓ 2.82-3.11 h in patients aged 15-63 years [26] [27] [28] . The smaller V ss observed in non-clinical studies [24] suggests that, with the same or lower CL rate, it will take longer for drug levels to become non-detectable in plasma, thereby explaining the longer duration of effect of MarzAA compared with eptacog alfa (activated). Although this might be at the potential risk of an increased peak concentration in plasma, it would not be a relevant concern with the subcutaneous administration route. The mechanism for the potential dose-dependent decreases in CL and V ss is not clear; it could be attributable to the binding of MarzAA to platelets or endothelial cells, with the binding becoming saturated as the concentration increases. Overall, the V ss for MarzAA was close to the volume of the vasculature, particularly at higher doses. In addition, the V ss for MarzAA at the highest doses was approximately half that of eptacog alfa (activated) [26] , suggesting that, when the same dose is administered, a higher concentration of MarzAA may be available in the plasma and at the site of bleeding. We have been unable to raise an antibody that distinguishes between MarzAA and eptacog alfa (activated) in preclinical and laboratory studies. Levels of eptacog alfa (activated) are expected to be negligible in the absence of treatment and in the non-bleeding state, and, furthermore, PK parameters were calculated with baselineadjusted PK concentration data, which would account for any background eptacog alfa (activated).
Treatment-related changes in PD endpoints were observed for the PT, the APTT, the TGA (lag time, peak, and ETP), TAT complexes, F 1+2 and, potentially, D-dimer. PD parameters requiring ex vivo activation steps, including the PT, APTT, and TGA, showed maximal changes around the time when the maximal FVIIa MarzAA, marzeptacog alfa (activated). TGA reference range, 3.2-7.8 min; D-dimer reference range, 0-500 ng mLÀ1; TAT complex reference range, 1-4.1 lg LÀ1. *n = 5 for TGA and D-dimer analysis -one subject was excluded from the pharmacodynamic analysis; n = 4 for TAT complex analysis -two subjects were excluded. The single occurrence of a positive ADA, based on the protocol operational definition, was weak, was transient, and had a negative result in titer characterization, but it was cross-reactive with eptacog alfa (activated) and native human FVII; however, it was not neutralizing. This subject's binding assay result at baseline was below the positive cut-off, but higher than those of the other subjects in the study. This trend continued throughout testing, and the day 60 postdose sample crossed over the positive cut-off criteria. The respective sample was positive during the confirmation step, but was negative during titer characterization. This subject did not have ADA present at the follow-up visit, and was negative in the FVIIa inhibitor assay at all scheduled time points, including day 60, and the FVII activity level was not reduced below the normal reference range at any visit, suggesting that this finding was not clinically relevant and was probably a false-positive result. A critical part of determining the clinical safety and efficacy of protein-based therapies is measuring their tendency to trigger antibody formation. Immunogenicity lessons from the clinical development of other rFVIIa agents, including BAY 86-6150 (with two amino acid substitutions -T106N and V253N) [29] and vatreptacog alfa (with three amino acid substitutions -V158D, E296V, and M298Q) [33, 34] , highlight the need for increased diligence regarding the presence of inhibitors with repeat dosing of MarzAA. In fact, this is an endpoint in the ongoing phase 2/3 study evaluating daily subcutaneous treatment with MarzAA for bleeding prophylaxis in patients with hemophilia A and B patients with inhibitors (ClinicalTrials.gov: NCT03407651).
These data indicate that MarzAA may be a promising candidate as a long-acting bypassing agent. This is encouraging, as there is a need for bypassing agents with favorable PK and hemostatic properties, including increased potency, to allow subcutaneous dosing and a prolonged duration of effect. MarzAA may potentially help address an existent unmet medical need in patients with FVII deficiency or hemophilia B with inhibitors, in whom the bispecific antibody emicizumab-kxwh (HEMLIBRA; Genentech, South San Francisco, CA, USA) cannot work, and in hemophilia A patients with inhibitors who may experience loss of efficacy with emicizumab.
Conclusion
MarzAA showed favorable safety, PK and PD parameters in this phase 1, first-in-human study, warranting further investigation, including the use of subcutaneous dosing. Moreover, no potential safety concerns were identified with MarzAA in the treated subjects. The observed single transient and weak ADA response with no neutralizing activity and no impact on safety was assessed as a false-positive result; however, immunogenicity should be closely monitored in future studies with MarzAA. Additional clinical trials have been initiated to evaluate the efficacy, PK, PD, bioavailability and safety of daily subcutaneous treatment with MarzAA for bleeding prophylaxis in adult subjects with hemophilia A and B with inhibitors. Addendum S. Arkin, F. Hua, and M. Scaramozza contributed to the study design. R. A. Gruppo, A. von Drygalski, L. Boggio, G. Tagariello, L. Nemes, and P. Chowdary were study investigators and enrolled subjects. R. A. Gruppo, A. von Drygalski, G. Tagariello, and P. Chowdary participated in the collection and assembly of data. R. A. Gruppo, S. Arkin, F. Hua, and M. Scaramozza performed data analysis and interpretation. All authors participated in the preparation of this manuscript, provided critical review and revisions, and granted approval for submission.
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